Guardant Health, Inc. $GH Shares Sold by World Investment Advisors

World Investment Advisors cut its stake in Guardant Health, Inc. (NASDAQ:GH) by 26.9% in the first quarter, HoldingsChannel reports. The institutional investor owned 11,909 shares of the company’s stock after selling 4,381 shares during the quarter. World Investment Advisors’ holdings in Guardant Health were worth $1,100,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. V Square Quantitative Management LLC purchased a new stake in shares of Guardant Health during the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC acquired a new position in Guardant Health during the fourth quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Guardant Health during the fourth quarter worth $31,000. Elyxium Wealth LLC purchased a new stake in Guardant Health during the fourth quarter worth $35,000. Finally, Parallel Advisors LLC boosted its position in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, insider John G. Saia sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total value of $2,130,200.00. Following the sale, the insider directly owned 45,950 shares of the company’s stock, valued at approximately $4,894,134.50. This trade represents a 30.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of Guardant Health stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the sale, the chief executive officer owned 2,012,919 shares of the company’s stock, valued at $254,231,669.70. This trade represents a 4.73% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 708,681 shares of company stock valued at $90,566,438. 5.60% of the stock is owned by corporate insiders.

Guardant Health Price Performance

Guardant Health stock opened at $156.17 on Thursday. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $174.08. The stock has a market capitalization of $20.71 billion, a P/E ratio of -46.07 and a beta of 1.59. The firm’s 50-day moving average is $124.35 and its two-hundred day moving average is $107.49.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on GH shares. BTIG Research lifted their price target on Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Royal Bank Of Canada started coverage on shares of Guardant Health in a report on Thursday, June 11th. They set an “outperform” rating and a $185.00 target price for the company. The Goldman Sachs Group started coverage on shares of Guardant Health in a research report on Friday, June 5th. They set a “buy” rating and a $165.00 target price for the company. Mizuho upped their price target on shares of Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a report on Monday, June 8th. Finally, Wolfe Research initiated coverage on shares of Guardant Health in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $153.74.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.